Therapeutic area intelligence for Nasopharyngeal Carcinoma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

TIM-3 →

Assets

gemcitabine →

TIGIT →

Recent signals(2)

ClinicalJuly 19, 2026

Phase I Study of JS001sc in Advanced Nasopharyngeal Carcinoma Shows Focus on Safety and Tolerability

A phase I clinical study is underway to evaluate the safety and tolerability of JS001sc, both as monotherapy and in combination with gemcitabine and cisplatin.

ClinicalJuly 12, 2026

EBV Reprograms Immune Escape in Nasopharyngeal Carcinoma, Impacting Immunotherapy Efficacy

EBV-driven immune reprogramming in NPC leads to poor responses to anti-PD-1 therapies due to alternative checkpoint exploitation.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Nasopharyngeal Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.